TWD 179.0
(-1.65%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 733.58 Million TWD | -32.12% |
2022 | 1.08 Billion TWD | 62.47% |
2021 | 667.51 Million TWD | 117.49% |
2020 | 306.91 Million TWD | 20.18% |
2019 | 255.37 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 287.8 Million TWD | -2.8% |
2024 Q1 | 307.61 Million TWD | 63.22% |
2023 Q4 | 188.45 Million TWD | -15.09% |
2023 FY | - TWD | -32.12% |
2023 Q3 | 221.95 Million TWD | 16.18% |
2023 Q2 | 191.05 Million TWD | 41.8% |
2023 Q1 | 134.73 Million TWD | -42.42% |
2022 FY | - TWD | 62.47% |
2022 Q4 | 233.99 Million TWD | 0.0% |
2021 FY | - TWD | 117.49% |
2020 FY | - TWD | 20.18% |
2019 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 402.69 Million TWD | -82.168% |
Maxigen Biotech Inc. | 177.09 Million TWD | -314.238% |
SciVision Biotech Inc. | 281.34 Million TWD | -160.74% |
Bionime Corporation | 179.78 Million TWD | -308.045% |
Pegavision Corporation | 2.91 Billion TWD | 74.86% |